Development and Translation of D-glucose as an MRI Contrast Agent for Multiple Sclerosis
D-葡萄糖作为多发性硬化症 MRI 造影剂的开发和转化
基本信息
- 批准号:10268261
- 负责人:
- 金额:$ 24.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-30 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAdverse effectsAffectAwardBlood - brain barrier anatomyBrainBrain regionCell NucleusChelating AgentsChemicalsChronicClinicClinicalContrast MediaDataDepositionDevelopmentDiagnosisDiseaseDisease ProgressionDoseEnhancing LesionEventEvolutionFund RaisingGadoliniumGliosisGlucoseGoalsImageImaging TechniquesInflammationInflammatoryInfusion proceduresIntravenousIntravenous infusion proceduresKidney DiseasesKidney FailureKnowledgeLaboratoriesLeadershipLesionMRI ScansMagnetic Resonance ImagingMeasuresMentorsMentorshipMethodsMindMinorMonitorMultiple SclerosisMultiple Sclerosis LesionsMusNephrogenic Systemic FibrosisNerve DegenerationNoisePathologicPathologyPatientsPatternPeriodicityPermeabilityPhasePhysiologyProcessPrognosisProtocols documentationProtonsRenal functionReportingResearchResearch ProposalsResolutionRiskScanningSeriesSignal TransductionStudentsSymptomsT2 weighted imagingTechniquesTestingTimeTissuesTrainingTranslatingTranslationsTreatment EfficacyWaterbasebiomaterial compatibilityblood-brain barrier disruptioncareercareer developmentclinical practicecohortcontrast enhancedcontrast imagingcostfollow-upglucose uptakegray matterhuman subjectimaging agentmagnetic fieldmultiple sclerosis patientnervous system disorderpeaceprogramsrecruitremyelinationskillssugartissue repairtumor
项目摘要
Project Summary
Multiple sclerosis (MS) is a disabling neurological disorder that is estimated to affect more than 2.3 million people
worldwide. Gadolinium (Gd) contrast enhanced MRI is routinely used in the clinics and is the most sensitive test
for establishing diagnosis, predicting prognosis and evaluating treatment efficacy of MS disease. While Gd based
contrast agents have demonstrated to be very safe, they have the potential for adverse effects in patients with
kidney diseases. In addition, it recently has been reported that the Gd agent can be deposited in deep gray
matter nuclei after repeated administration to patients with intact renal function. Based on such issues, there is
an urgent need to develop safe alternative contrast agents, especially for MS disease since patients are
subjected to periodic scans. The overall goal for this research proposal is to develop and translate to the
clinic the use of D-glucose as an intravenous MRI contrast agent for imaging blood-brain-barrier (BBB)
disruption in MS. In addition, since the size of D-glucose molecules are smaller than Gd agents, they may be
more amenable to leak into lesions with minor BBB disruption, hence provide a more sensitive means to detect
lesions at an earlier stage.
Preliminary data on mice and human subjects show that intravenous infusion of D-glucose provides MRI
contrast that distinguishes the tumor and MS lesions from the unaffected brain region using the chemical
exchange saturation transfer (CEST) MRI technique. The data shows that the CEST contrast is enhanced upon
D-glucose infusion in tumors and some MS lesions where BBB disruption is suspected. To achieve the goal of
the proposal, Dr. Xu will develop 3D whole brain, high resolution CEST MRI techniques that are suitable for
imaging MS lesions first at 7 Tesla and subsequently translate the technique to 3 Tesla scanners for patient
studies. During the R00 phase, the lesion enhancement patterns for both glucose CEST and Gd will be compared
in a cohort of MS patients to validate the feasibility of using D-glucose as a contrast agent.
The successful completion of this project will: 1) provide a natural and biodegradable MRI contrast agent
for imaging MS lesions; 2) provide a 3D whole brain CEST MRI protocol for imaging MS and other neurological
disorders; 3) provide a possible means to capture MS lesions at an earlier stage than conventional Gd agents
and enhance our understanding of the correlation between MS pathology and clinical MRI findings. The new
skills and knowledge that Dr. Xu will develop during the training period of the project will not only be crucial for
the successful completion of the project and her immediate scientific goals, they will also become the pillars for
the research program she will build in her own independent laboratory. The career development activity and
mentorship during the award period will prepare her for the practical aspects of research leadership, mentoring
and fund raising, which are critical for her career as an independent research leader.
项目摘要
多发性硬化症(MS)是一种致命的神经系统疾病,估计会影响超过230万人
全世界。 Gadolinium(GD)对比度增强MRI通常在诊所中使用,是最敏感的测试
用于建立诊断,预测预后和评估MS疾病的治疗功效。而GD基于GD
对比剂已经证明非常安全,它们有可能对
肾脏疾病。此外,最近有报道说GD代理可以沉积在深灰色中
重复给具有完整肾功能的患者进行重复给药后的物质核。基于此类问题,有
迫切需要开发安全的替代对比剂,尤其是对于MS疾病,因为患者是
进行定期扫描。该研究建议的总体目标是发展并转化为
诊所将D-葡萄糖用作静脉内MRI对比剂对血脑屏障成像(BBB)
MS中断。另外,由于D-葡萄糖分子的大小小于GD剂,因此它们可能是
更适合泄漏到小BBB中断的病变中,因此提供了一种更敏感的方法来检测
病变在较早的阶段。
关于小鼠和人类受试者的初步数据表明,静脉输注D-葡萄糖可提供MRI
对比,将肿瘤和MS病变与未受影响的大脑区域区分开
交换饱和转移(CEST)MRI技术。数据表明,CEST的对比度增强了
肿瘤中的D-葡萄糖输注和一些怀疑BBB破坏的MS病变。实现目标
该提议将开发3D整个大脑,高分辨率CEST MRI技术,适合
首先将MS病变成像在7 Tesla处,然后将技术转换为3种特斯拉扫描仪的患者
研究。在R00阶段,将比较葡萄糖CEST和GD的病变增强模式
在一组MS患者中,以验证使用D-葡萄糖作为对比剂的可行性。
该项目的成功完成将:1)提供自然且可生物降解的MRI对比剂
用于成像MS病变; 2)提供3D整个大脑CEST MRI方案,用于成像MS和其他神经系统
疾病; 3)提供了一种可能在更早的阶段捕获MS病变的方法
并增强我们对MS病理学与临床MRI发现之间相关性的理解。新的
Xu博士将在项目培训期间发展的技能和知识不仅至关重要
该项目的成功完成及其直接的科学目标,它们也将成为
她将在自己的独立实验室中构建的研究计划。职业发展活动和
奖励期间的指导将使她为研究领导的实际方面和指导做好准备
和筹款,这对于她作为独立研究领袖的职业至关重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xiang Xu其他文献
Xiang Xu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xiang Xu', 18)}}的其他基金
Non-invasive Magnetic Resonance Imaging of Glycogen in the Human Liver
人类肝脏中糖原的无创磁共振成像
- 批准号:
10727928 - 财政年份:2023
- 资助金额:
$ 24.88万 - 项目类别:
Development and Translation of D-glucose as an MRI Contrast Agent for Multiple Sclerosis
D-葡萄糖作为多发性硬化症 MRI 造影剂的开发和转化
- 批准号:
10247299 - 财政年份:2020
- 资助金额:
$ 24.88万 - 项目类别:
Development and Translation of D-glucose as an MRI Contrast Agent for Multiple Sclerosis
D-葡萄糖作为多发性硬化症 MRI 造影剂的开发和转化
- 批准号:
10457448 - 财政年份:2020
- 资助金额:
$ 24.88万 - 项目类别:
Development and Translation of D-glucose as an MRI Contrast Agent for Multiple Sclerosis
D-葡萄糖作为多发性硬化症 MRI 造影剂的开发和转化
- 批准号:
9527559 - 财政年份:2018
- 资助金额:
$ 24.88万 - 项目类别:
相似国自然基金
基因与家庭不利环境影响儿童反社会行为的表观遗传机制:一项追踪研究
- 批准号:
- 批准年份:2020
- 资助金额:58 万元
- 项目类别:面上项目
不利地质结构对地下洞室群围岩地震响应影响研究
- 批准号:51009131
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
列车制动力对铁路桥梁的作用机理及最不利影响的研究
- 批准号:50178004
- 批准年份:2001
- 资助金额:23.0 万元
- 项目类别:面上项目
相似海外基金
Ovarian impacts of extreme heat and co-exposure to climate change-induced harmful algal bloom toxins (Admin Supplement to R01ES032144)
极端高温和共同暴露于气候变化引起的有害藻华毒素对卵巢的影响(R01ES032144 的管理补充)
- 批准号:
10838834 - 财政年份:2023
- 资助金额:
$ 24.88万 - 项目类别:
Early Life Determinants of Child Health: A New Denver-Based Cohort
儿童健康的早期决定因素:丹佛的一个新队列
- 批准号:
10745631 - 财政年份:2023
- 资助金额:
$ 24.88万 - 项目类别:
Teratogenicity assessment of new antiviral drugs using 3D morphogenesis models
使用 3D 形态发生模型评估新型抗病毒药物的致畸性
- 批准号:
10741474 - 财政年份:2023
- 资助金额:
$ 24.88万 - 项目类别:
Injury of blood brain and alveolar-endothelial barriers caused by alcohol and electronic cigarettes via purinergic receptor signaling
酒精和电子烟通过嘌呤受体信号传导引起血脑和肺泡内皮屏障损伤
- 批准号:
10638221 - 财政年份:2023
- 资助金额:
$ 24.88万 - 项目类别:
Multifunctional Nanoparticle Platform to Prevent Alcohol-Associated HCC Development
多功能纳米颗粒平台可预防酒精相关的 HCC 发展
- 批准号:
10736984 - 财政年份:2023
- 资助金额:
$ 24.88万 - 项目类别: